Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Guldane Cengiz Seval, Klara Dalva, Dilek Oz, Sule Mine Bakanay, Ender Soydan, Gunhan Gurman, Osman Ilhan, Meral Beksac

Blood (2021) 138 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2021-148879

Published: 2021

Journal Articles

Residual Clonal Plasma Cells Detected By Flow Cytometry at 10 -4 level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival

Guldane Cengiz Seval, Klara Dalva, MD, Sule Mine Bakanay, Mustafa Merter, MD, Ugur Sahin, MD, Atilla Uslu, MD, Cemaleddin Ozturk, Osman Ilhan, MD, Meral Beksac, MD

Blood (2018) 132 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2018-99-111794

Published: 2018

Journal Articles

Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values

Meral Beksac, MD, Mehmet Gunduz, MD, Mehmet Ozen, MD, Sule Mine Bakanay Ozturk, MD, Ozlem Kucuk, MD, Elgin Ozkan, MD

Blood (2014) 124 (21): 3983.

https://doi.org/10.1182/blood.V124.21.3983.3983

Published: 2014

Journal Articles

Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A03, B44) or Poorer (HLA B51, C04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers

Elif Suyani, MD, Sule Mine Bakanay, MD, Klara Dalva, MD, Ezgi Cakmak, MSc, Rauf Haznedar, MD, Gulsan Sucak, MD, Meral Beksac, MD

Blood (2012) 120 (21): 4904.

https://doi.org/10.1182/blood.V120.21.4904.4904

Published: 2012

Journal Articles

Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma.

Sule Mine Bakanay, MD, Klara Dalva, MD, Berna Elif Koksoy, MD, Erol Ayyildiz, Muhit Ozcan, M.D., Osman Ilhan, MD, Meral Beksac, MD

Blood (2012) 120 (21): 3024.

https://doi.org/10.1182/blood.V120.21.3024.3024

Published: 2012

Journal Articles

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.

Pervin Topcuoglu, MD, Klara Dalva, M.D., Sule Mine Bakanay, MD, Sinem Civriz Bozdag, M.D., Onder Arslan, M.D., Muhit Ozcan, M.D., Mutlu Arat, MD, Meral Beksac, MD, Gunhan Gurman, M.D.

Blood (2009) 114 (22): 4846.

https://doi.org/10.1182/blood.V114.22.4846.4846

Published: 2009

Journal Articles

Factors Involved in Response to Thalidomide in Myelodysplastic Syndrome: Impace of HLA and Prognostic Factors

Sule Mine Bakanay, MD, Klara Dalva, MD, Pervin Topcuoglu, MD, Sinem Civriz-Bozdag, MD, Mutlu Arat, MD, Meral Beksac, MD, Gunhan Gurman, MD

Blood (2008) 112 (11): 5079.

https://doi.org/10.1182/blood.V112.11.5079.5079

Published: 2008

NARROW

Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Residual Clonal Plasma Cells Detected By Flow Cytometry at 10 -4 level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival

Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values

Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A03, B44) or Poorer (HLA B51, C04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers

Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma.

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.

Factors Involved in Response to Thalidomide in Myelodysplastic Syndrome: Impace of HLA and Prognostic Factors

Email alerts

ASH Publications

American Society of Hematology

Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Residual Clonal Plasma Cells Detected By Flow Cytometry at 10 -4 level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival

Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values

Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers

Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma.

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.

Factors Involved in Response to Thalidomide in Myelodysplastic Syndrome: Impace of HLA and Prognostic Factors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A03, B44) or Poorer (HLA B51, C04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers